| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaids (note 5) | 355,204 | |||
| Short-term investments (note 4) | 23,667,161 | |||
| Receivables | 527,148 | |||
| Cash and cash equivalents | 85,952,587 | |||
| Total current assets | 110,502,100 | |||
| Operating lease right-of-use asset (note 7) | 0 | |||
| Total assets | 110,502,100 | |||
| Accounts payable and accrued liabilities (note 6) | 1,599,955 | |||
| Total current liabilities | 1,599,955 | |||
| Total liabilities | 1,599,955 | |||
| Accumulated deficit | -226,914,172 | |||
| Common shares 44,388,550 issued and outstanding (september 30, 2024 - 44,388,550) (note 8) | 279,862,420 | |||
| Additional paid-in capital (note 8) | 58,050,904 | |||
| Accumulated other comprehensive loss | -2,097,007 | |||
| Total stockholders equity | 108,902,145 | |||
| Total liabilities and shareholders' equity | 110,502,100 | |||
ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. (EPIX)